Research programme: biodefence anti-infectives - Microbiotix

Drug Profile

Research programme: biodefence anti-infectives - Microbiotix

Alternative Names: Yersinia pestis cell surface plasminogen activator inhibitors - Microbiotix; Biodefence DNA helicase inhibitors - Microbiotix; Biodefence DNA replicase inhibitors - Microbiotix; Biodefense anti-infectives - Microbiotix; Quinolone-based inhibitors of BoNT/A LC - Microbiotix

Latest Information Update: 08 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Microbiotix
  • Class Imidazolines; Indoles; Nucleosides; Quinolones; Small molecules
  • Mechanism of Action Adenosylhomocysteinase inhibitors; Botulinum toxin inhibitors; DNA helicase inhibitors; DNA helicase-primase inhibitors; DNA topoisomerase IV inhibitors; DNA-directed DNA polymerase inhibitors; Metalloprotease inhibitors; Plasminogen activator inhibitors; Toll-like receptor 5 antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Anthrax; Botulism; Burkholderia infections; Ebola virus infections; Gram-negative infections; Yersinia infections

Most Recent Events

  • 25 Sep 2012 Early research is ongoing in USA
  • 01 Apr 2011 Microbiotix receives a Phase I SBIR grant from the US NIH to support development of small molecule, quinolone based inhibitors of Botulinum neurotoxin A for treatment of botulinum poisoning
  • 01 Apr 2011 Early research in Botulism in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top